Butaperazine

Butaperazine

SCHEMBL119995

CCCC(=O)c1ccc2c(c1)N(CCCN1CCN(C)CC1)c1ccccc1S2

nearest known ligand 0.73

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH1 P35367 7/20 0.67
HTR1A P08908 6/20 0.67
DRD2 P14416 6/20 0.67
ADRA2C P18825 6/20 0.67
SLC6A2 P23975 6/20 0.67
HTR2A P28223 6/20 0.67
SLC6A4 P31645 6/20 0.67
ADRA1A P35348 6/20 0.67
DRD3 P35462 6/20 0.67
SLC6A3 Q01959 6/20 0.67
KCNH2 Q12809 6/20 0.67
ADRA2A P08913 5/20 0.67
DRD1 P21728 5/20 0.67
ADRA2B P18089 5/20 0.67
HTR2B P41595 4/20 0.67
HRH3 Q9Y5N1 4/20 0.67
MLNR O43193 2/20 0.67
ESR1 P03372 2/20 0.67
PTGS2 P35354 1/20 0.67
KDM1A O60341 3/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Butaperazine SCHEMBL28086241 1.00 HRH1 (0.67) HRH1HTR1ADRD2ADRA2CSLC6A2
Butaperazine SCHEMBL29710903 1.00 HRH1 (0.67) HRH1HTR1ADRD2ADRA2CSLC6A2
Butaperazine SCHEMBL31153317 1.00 HRH1 (0.67) HRH1HTR1ADRD2ADRA2CSLC6A2
Butaperazine SCHEMBL120744 0.94 LMNA (0.72) HRH1HTR1ADRD2ADRA2CSLC6A2
Butaperazine SCHEMBL120743 0.94 LMNA (0.72) HRH1HTR1ADRD2ADRA2CSLC6A2
Thioproperazine SCHEMBL13723252 0.90 DRD3 (0.79) HRH1HTR1ADRD2ADRA2CSLC6A2
SCHEMBL18309819 0.88 HRH1 (0.69) HRH1HTR1ADRD2ADRA2CSLC6A2
SCHEMBL141601 0.87 HTR1A (0.86) HRH1HTR1ADRD2ADRA2CSLC6A2
SCHEMBL26837052 0.85 HRH1 (0.69) HRH1HTR1ADRD2ADRA2CSLC6A2
Carphenazine SCHEMBL1458434 0.84 HRH1 (0.81) HRH1HTR1ADRD2ADRA2CSLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1881 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4618973-A1 METHODS OF SWITCHING NEUROPSYCHIATRIC MEDICATIONS USING ULOTARONT Sumitomo Pharma America, Inc. (US) 2025-09-24 EP claimed
US-20250179064-A1 BENZOQUINOLONE INHIBITORS OF VMAT2 AUSPEX PHARMACEUTICALS LLC 2025-06-05 US claimed
US-12178804-B2 Salts of cycloserine compounds and applications thereof SYNEURX INTERNATIONAL (TAIWAN) CORP. (TW) 2024-12-31 US claimed
WO-2024107681-A1 METHODS OF SWITCHING NEUROPSYCHIATRIC MEDICATIONS USING ULOTARONT SUMITOMO PHARMA AMERICA, INC. (US) 2024-05-23 WO claimed
EP-3529229-B1 POLYMORPHIC FORMS OF SODIUM BENZOATE AND USES THEREOF SYNEURX INT TAIWAN CORP (TW) 2024-04-17 EP claimed
US-20240000810-A1 USE OF CANNABINOIDS IN THE TREATMENT OF TOURETTE SYNDROME AND TIC DISORDERS Orcosa Inc. (US) 2024-01-04 US claimed
US-20230321073-A1 COMPOSITIONS AND METHODS FOR TREATING METABOLIC DYSREGULATION Response IP Holding Company, LLC (US) 2023-10-12 US claimed
US-20230218623-A1 SALTS OF NEUROCEUTICALS AND USES THEREOF SYNEURX INTERNATIONAL (TAIWAN) CORP. (TW) 2023-07-13 US claimed
EP-4192579-A2 COMPOSITIONS AND METHODS FOR TREATING METABOLIC DYSREGULATION Response IP Holding Company, LLC (US) 2023-06-14 EP claimed
EP-4146656-A1 SALTS OF NEUROCEUTICALS AND USES THEREOF Syneurx International (Taiwan) Corp. (TW) 2023-03-15 EP claimed
EP-0174342-B1 BRAIN-SPECIFIC ANALOGUES OF CENTRALLY ACTING AMINES UNIVERSITY OF FLORIDA (US) 1989-12-20 EP claimed
EP-0263873-A4 ANTI-PATHOGENIC BLOOD COLLECTION SYSTEM AND METHOD. AL-SIOUFI HABIB 1989-07-11 EP claimed
EP-0263873-A1 ANTI-PATHOGENIC BLOOD COLLECTION SYSTEM AND METHOD AL-SIOUFI, Habib (US) 1988-04-20 EP claimed
WO-1987006119-A1 ANTI-PATHOGENIC BLOOD COLLECTION SYSTEM AND METHOD AL SIOUFI HABIB 1987-10-22 WO claimed
EP-0180364-A2 Pharmaceutical compositions containing phenothiazines RECKITT AND COLMAN PRODUCTS LIMITED (GB) 1986-05-07 EP claimed
EP-0174342-A1 BRAIN-SPECIFIC ANALOGUES OF CENTRALLY ACTING AMINES. UNIV FLORIDA (US) 1986-03-19 EP claimed
WO-1985003937-A1 BRAIN-SPECIFIC ANALOGUES OF CENTRALLY ACTING AMINES UNIVERSITY OF FLORIDA (US) 1985-09-12 WO claimed
US-4407800-A TRYPANOCIDES UNIVERSITY OF VIRGINIA ALUMNI PATENTS FOUNDATION (US) 1983-10-04 US claimed
US-4249003-A Process for polycyclic amines AKTIEBOLAGET LEO (SE) 1981-02-03 US claimed
US-4175119-A Composition and method to prevent accidental and intentional overdosage with psychoactive drugs PORTER GARRY L 1979-11-20 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250179064-A1 BENZOQUINOLONE INHIBITORS OF VMAT2 ACAT2, CPT1A, SLC18A2 HRH1 3242/4885HTR1A 747/4885DRD2 2127/4885
US-20230321073-A1 COMPOSITIONS AND METHODS FOR TREATING METABOLIC DYSREGULATION LIPC, CPT1A, CETP HRH1 4797/4885HTR1A 3890/4885DRD2 4836/4885
US-20230218623-A1 SALTS OF NEUROCEUTICALS AND USES THEREOF SLC1A2, GABRA6, GABRA2 HRH1 1889/4885HTR1A 932/4885DRD2 1923/4885
US-12178804-B2 Salts of cycloserine compounds and applications thereof TST, RIMKLA, PSPH HRH1 2093/4885HTR1A 336/4885DRD2 930/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.